US FDA revokes authorization for four COVID antibody drugs

US FDA revokes authorization for four COVID antibody drugs The U.S. Food and Drug Administration has revoked the emergency use authorization for four COVID-19 antibody-based drugs, including those from Eli Lilly and Regeneron . Reuters Reuters

...

The shelf life of the drugs had expired and they had not been authorized for administration to patients for more than a year due to the circulation of non-susceptible variants, the FDA said in letters dated earlier this month and posted on its website on Monday.

The FDA revoked the authorization for Lilly's bebtelovimab, AstraZeneca's (AZN.L), opens new tab Evusheld, GSK's (GSK.L) , opens new tab sotrovimab and Regeneron's REGEN-COV.